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Understanding the Role of Endothelial
Progenitor Cells in Percutaneous Coronary Intervention
Gareth J. Padfield, BMSC, MBCHB, David E. Newby, MD, PHD, Nicholas L. Mills, PHD
Edinburgh, United Kingdom
Percutaneous coronary intervention is associated with mechanical endovascular injury and endothelial denuda-
tion. Re-endothelialization is essential for restoration of normal vascular homeostasis and regulation of neointi-
mal hyperplasia. The endothelial progenitor cell recently emerged as an important component of the response
to vascular injury, having the potential to accelerate vascular repair through rapid re-endothelialization. There
remains considerable uncertainty over the precise identity and function of endothelial progenitor cells, and har-
nessing their therapeutic potential remains a challenge. A better understanding of the role of circulating progeni-
tors in the response to vascular injury is necessary if we are to develop effective strategies to enhance vascular
repair after percutaneous coronary intervention. In this review, we examine the preclinical and clinical evidence
of a role for bone marrow-derived putative endothelial progenitor cells after iatrogenic vascular injury associated
with balloon angioplasty and stent deployment. Therapies designed to mobilize endothelial progenitors or to in-
crease their ability to home to the site of stent implantation may have a role in the future management of pa-
tients undergoing percutaneous coronary intervention. (J Am Coll Cardiol 2010;55:1553–65) © 2010 by the
American College of Cardiology Foundation
ublished by Elsevier Inc. doi:10.1016/j.jacc.2009.10.070a
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clthough percutaneous coronary intervention (PCI) im-
roves myocardial perfusion and clinical outcomes in pa-
ients with ischemic heart disease, the treated coronary
rtery segment inevitably undergoes significant mechanical
rauma. Endothelial denudation and endovascular laceration
y rigid stent struts and high-pressure balloon inflations
isturb vascular function and initiate an intensive local inflam-
atory response. Vascular injury may result in neointimal
yperplasia, in-stent restenosis (ISR), and the potentially
atastrophic complication of acute stent thrombosis. Re-
ndothelialization, a necessary component of restoring vascular
omeostasis, was previously thought to occur purely through
he migration and proliferation of mature endothelial cells
djacent to regions of endothelial denudation (1). However,
ttention has recently focused on a novel mechanism of
ascular repair involving a bone marrow-derived precursor or
tem cell: the endothelial progenitor cell (EPC). It has been
roposed that EPCs are mobilized in response to vascular
njury and can home to sites of endothelial denudation (2) and
acilitate re-endothelialization (3). The discovery of the EPC
as launched a new field of cardiovascular research, changed
ur understanding of vascular repair mechanisms, and offers
xciting and novel approaches to manage cardiovascular disease
rom the Centre for Cardiovascular Science, Edinburgh University, Edinburgh,
nited Kingdom. This work was supported by the British Heart Foundation
PG/07/017/22405); and Chest Heart and Stroke Scotland (RES07/A106).g
Manuscript received July 8, 2009; revised manuscript received October 14, 2009;
ccepted October 17, 2009.nd the complications associated with modern revasculariza-
ion strategies.
CI and Vascular Injury
dverse cardiac events after PCI continue to be problematic
espite advances in stent design and adjunctive pharmaco-
herapy. The incidence of angiographic restenosis after PCI
s approximately 11% and has been reported to be as high as
9% in higher risk populations using bare-metal stents (4).
tent thrombosis, although a relatively rare complication of
CI, can still occur in as many as 2% of cases and has
otentially devastating and fatal consequences (5). These
omplications arise, in part, as sequelae of the vascular
rauma that occurs during PCI as a result of the necessary
igh-pressure balloon inflations and forceful apposition of
omparatively rigid stent struts against the vessel wall that
eave the treated segment of vessel denuded of its endothe-
ium with a consequent disruption of normal vascular
unction. Stent struts may cause laceration of the internal
lastic lamina that may extend through the tunica media to
he external elastic lamina (6). Vessel injury causes activa-
ion and aggregation of platelets and thrombus formation,
hich may lead to acute or subacute stent occlusion (7).
ascular injury triggers both local (6) and systemic (8)
nflammation with a typical cellular response of a rapid
nflux of neutrophils followed by the migration of mono-
ytes and macrophages into the vessel wall. Cytokine and
rowth factor release stimulates the migration and prolifer-
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Endothelial Progenitor Cells and PCI April 13, 2010:1553–65ation of intimal smooth muscle
cells and fibroblasts, and the re-
cruitment of adventitial myofi-
broblasts, encouraging neointi-
mal hyperplasia and ISR (9).
The process of stent integration
into the vessel wall has been ele-
gantly characterized using scan-
ning electron microscopy (10).
During the first 6 weeks, a thin
multilayered thrombus is present
between the vascular lumen and
arterial wall, and an increasing
concentration of smooth muscle
cells and extracellular matrix can
be detected as time progresses. Six
to 12 weeks from stent implanta-
tion, the thrombus resolves and
endothelial cells begin to cover the
stented segment. Complete re-
ndothelialization takes place approximately 3 months after
tent implantation, at which time the number of smooth
uscle cells begins to decrease. The endothelium is not only
ntegral to normal endogenous fibrinolysis and vasomotor
unction, but also provides a protective barrier for smooth
uscle cells against circulating growth factors and secretes a
umber of inhibitory factors that prevent smooth muscle
ell proliferation. Rapid re-endothelialization is therefore of
ritical importance to restore normal vascular function,
educe vascular inflammation, and prevent adverse remod-
ling after PCI (11). It is now clear that bone marrow-
erived cells are an important component of the cellular
esponse to vascular injury with the potential to enhance
e-endothelialization after coronary intervention.
PCs
one marrow-derived cells with the capacity to differentiate
nto mature cell types exist within the adult circulation. This
oncept has been confirmed primarily through studies of bone
arrow transplant recipients in whom appropriately differen-
iated cells of donor origin integrate into host structures, such
s the heart and lung (12,13). Contrary to the traditional
aradigm of re-endothelialization, it is now clear that this same
rinciple applies to vascular endothelial cells. The term EPC
as first used by Asahara et al. (2) in 1997 and has subse-
uently been applied interchangeably to a variety of cell
opulations by different investigators. Considerable ambiguity
egarding the optimal definition of an EPC continues to cause
roblems in the field. Broadly speaking, 2 approaches to
dentify EPCs have predominated: 1) identifying cells bearing
urface markers that indicate both cellular naïveté and endo-
helial origin; and 2) inferring the presence of endothelial
recursors within a given cell population by the identification
f cells bearing mature endothelial characteristics after a period
Abbreviations
and Acronyms
EC-CFU  endothelial cell
colony-forming unit
ECFC  endothelial colony-
forming cell
eNOS  endothelial nitric
oxide synthase
EPC  endothelial
progenitor cell
G-CSF  granulocyte
colony-stimulating factor
ISR  in-stent restenosis
KDR  kinase domain
receptor
PCI  percutaneous
coronary intervention
VEGF  vascular
endothelial growth factorf culture under angiogenic conditions. iurface markers. A detailed discussion of the controversies
urrounding EPCs and their definition is outside the scope
f this review. EPCs were originally defined by the expres-
ion of CD34 and kinase domain receptor (KDR), the
xtracellular domain of vascular endothelial growth factor
eceptor-2, as these cell surface markers were thought to
ndicate cellular naïveté and a vascular phenotype, respec-
ively (Table 1) (2). Just as endothelial function is integral to
he maintenance of normal vascular homeostasis, EPC
egulation seems to be similarly important. Concentrations
f circulating CD34KDR cells are decreased in patients
ith traditional cardiovascular risk factors including ciga-
ette smoking, elevated low-density lipoprotein cholesterol
14), diabetes mellitus (15), and hypertension (16). Indeed,
here seems to be a cumulative effect of multiple cardiovas-
ular risk factors on concentrations of CD34KDR cells
14), with levels markedly decreased in patients with overt
therosclerotic disease of the coronary and peripheral circu-
ation (17). A robust association has been demonstrated
etween a high circulating concentration of CD34KDR
ells and freedom from myocardial infarction, hospitaliza-
ion, revascularization, and cardiovascular death in patients
ith coronary artery disease. Additionally, the predictive
alue of CD34KDR cell concentration is independent
f traditional cardiovascular risk factors (18,19). Both
D34KDR cells (14) and CD133KDR cells (20) de-
rease with advancing age, although, interestingly, when pa-
ients are matched for biological characteristics, in particular,
ngiographic severity of coronary disease, chronological age
eems less important (21). Finally, it seems that EPC biology
s in part inherited, with apparently healthy offspring of
atients with coronary artery disease having reduced levels of
D34KDR cells compared with the offspring of healthy
ontrols (22).
Because CD34 and KDR are also expressed on circulat-
ng mature endothelial cells (23), an additional marker of
ellular naïveté, CD133, has been suggested as a means of
nsuring the identity of an EPC. CD133 is a precursor of an
ndothelial cell-like phenotype and has been used either
lone or in combination with CD34 and KDR as a
efinition for EPCs by numerous investigators (24–26).
owever, the rarity of these cells in the circulation makes
hem difficult to identify reliably and therefore a less
ractical candidate for therapeutic use. Furthermore, recent
tudies suggest that CD133 identifies a purely hematopoi-
tic cell line and that these cells are in fact not capable of
orming a true endothelial phenotype (27,28).
Cells expressing CD14, a receptor for endotoxin (29),
ave a predominant monocytic phenotype and have been
he subject of much interest in the EPC literature. CD14
ells are 10 times more abundant in the peripheral blood
han CD34 cells, are highly plastic, and have the ability to
dopt a variety of mature phenotypic and functional char-
cteristics, including those of endothelial cells under the
ight environmental cues (30–35). Several studies have
ndicated a role for monocytes in the repair of endothelial
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April 13, 2010:1553–65 Endothelial Progenitor Cells and PCInjury and restoration of function (32,34,36–41); however,
t is our view that CD14 cells accelerate vascular repair
hrough the secretion of angiogenic growth factors rather
han by differentiating into true endothelial cells.
unctional phenotype. Functional assays of EPCs have
een widely used to enumerate EPCs (Fig. 1). The most
ommon is the endothelial cell colony-forming unit (EC-
FU) assay popularized by Hill et al. (42). EC-CFUs are
enerated from a nonadherent population of mononuclear cells
ultured on fibronectin and exhibit endothelial cell-like char-
cteristics such as expression of CD31, CD141, CD105,
D146, CD144, von Willebrand factor, Tie-2, KDR, CD34,
nd E-selectin and an ability to bind lectins and take up
cetylated low-density lipoprotein (Table 1). EC-CFUs were
herefore thought to be endothelial cells formed from circulat-
ng progenitor cells. However, it is now recognized that many
f the surface antigens used to define mature endothelial cells
re nonspecific and are shared by circulating monocytes in
eripheral blood (43). EC-CFUs are in fact composed of
onocytes and angiogenic lymphocytes (36,44) and have little
apacity to form perfusing vessels or incorporate directly into
ascular structures (37). EC-CFUs exhibit phagocytic activity
nd avidly secrete angiogenic factors, such as vascular endo-
helial growth factor (VEGF), stromal derived factor-1, matrix
haracteristics Used to Identify Putative Endothelial Progenitor CeTable 1 Characteristics Used to Identify Putative Endothelial P
Identifier Distribution
CD45 Leukocytes A s
CD14 Monocytes, macrophages,
some neutrophils
En
CD115 Monocytes, macrophages Re
CD117 (c-Kit) Hematopoietic stem and progenitor cells Re
CD133 Hematopoietic stem and progenitor cells Un
CD34 Hematopoietic stem and progenitor cells,
capillary endothelium
Int
CD31 Leukocytes, platelets, endothelium Ad
Acetylated low-density
lipoprotein uptake
Macrophages, monocytes, endothelium N/
Ulex binding Macrophages, monocytes, endothelium N/
CD105 Endothelium, activated macrophages,
smooth muscle
Co
CD141 Endothelium, smooth muscle, monocytes,
and neutrophils
Bin
von Willebrand factor Endothelium, platelets He
Tie-2 (CD202) Endothelium, monocytes, stem cells An
CD146 Endothelium, melanoma cells,
dendritic cells
Int
E-selectin (CD62E) Endothelium Ad
CD144 Endothelium Int
VEGFR-2 (CD309, KDR, Flk1) Endothelium Re
Endothelial nitric oxide synthase Endothelium En
SF  colony-stimulating factor; N/A  not available; TNF  tumor necrosis factor.etalloproteinase-9, interleukin-8, hepatocyte-like growth tactor, granulocyte colony-stimulating factor (G-CSF), and
ranulocyte-macrophage colony-stimulating factor. All these
actors have been implicated in the mobilization of precursors
rom the bone marrow and the acceleration of angiogenesis
32,44). Nevertheless, EC-CFUs are reduced in patients with
oronary artery disease (45), diabetes mellitus (46), and hyper-
ension (47). Increased EC-CFUs are associated with better
ascular function (42) and are mobilized in response to cardio-
ascular stress, including discrete vascular injury caused by
ngioplasty (48–51). The EC-CFU assay therefore serves as a
arker of cardiovascular health and possibly indicates an
ndividual’s capacity to exert a hematopoietic and angiogenic
esponse to tissue injury, but it is not a direct measure of
ifferentiating or proliferating EPCs. As such, EC-CFU is an
nappropriate name for this population of cells, but given the
ack of an alternative, we use this nomenclature in the interests
f maintaining consistency with existing literature.
Interest has recently been drawn toward the late out-
rowth EPC or endothelial colony-forming cell (ECFC)
Fig. 1). ECFCs are derived from mononuclear cells but
iffer from EC-CFUs in that they arise from an adherent
opulation cultured on type I collagen and appear after 2 to
weeks of culture. Although ECFCs share many pheno-
ypic characteristics with EC-CFU (52), they do not express
itor Cells
Function
g molecule regulating leukocyte differentiation and proliferation Hematopoietic
receptor regulating inflammatory cytokine production such as
monocytes
for macrophage-CSF regulating myeloid proliferation and
ntiation
for stem cell factor; stimulates cellular proliferation
lar adhesion molecule; binds E- and L-selectins and is thought to
te leukocyte/endothelial interactions
molecule thought to be important for transendothelial cellular
ion to sites on acute inflammation
gocytic process occurring in myeloid and endothelial cells
ochemical stain
nt of transforming growth factor-beta receptor 1; important
tor of angiogenesis
ombin and activates protein C and initiates anticoagulant
ays
sis
tin-1 receptor; regulates vessel remodeling and maintains
ar integrity
lar adhesion molecule
molecule regulating leukocyte/endothelial interactions and
fficking to sites of inflammation
lar adhesion molecule regulating endothelial permeability and
ration
n of endothelial adhesion and signaling; essential for embryonic
ar development
c generation of nitric oxide Endothelialllsrogen
ignalin
dotoxin
TNF by
ceptor
differe
ceptor
known
ercellu
regula
hesion
migrat
A; pha
A; hist
nstitue
regula
ds thr
pathw
mosta
giopoie
vascul
ercellu
hesion
cell tra
ercellu
prolife
gulatio
vascul
zymatihe hematopoietic marker CD45 or myeloid/macrophage
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Endothelial Progenitor Cells and PCI April 13, 2010:1553–65arkers such as CD14 and CD115 and do not exhibit
hagocytic function. ECFCs arise from nonhematopoietic
ells negative for CD133 and the panleukocyte marker
D45, but expressing CD34 and KDR (27). Enrichment of
nsorted mononuclear preparations for CD45CD34
ells increases the frequency of ECFCs by approximately
00% compared with abolition of ECFC growth in the
D45 fraction (27). Of the populations so far identified,
he CD45CD34-derived ECFCs most accurately fulfills
he criteria of an EPC. They conform to an endothelial
henotype and morphology, are derived from bone marrow
53), have robust proliferative potential (54,55), and are
apable of forming perfusing vessels in vivo (37). ECFCs
re mobilized within the first few hours after myocardial
nfarction (56,57) and have been positively correlated with
he severity of coronary artery disease in patients undergoing
oronary angiography (58). However, their pathophysiolog-
cal relevance or therapeutic potential remains unclear.
CFCs and CD45CD34 cells represent a potentially
mportant but understudied component of endogenous
Figure 1 Early Versus Late Outgrowth Endothelial Cell Colonies
(A) The endothelial cell colony-forming unit (EC-CFU) assay. (A). EC-CFUs are gene
appear some 5 to 7 days into culture. EC-CFUs exhibit endothelium-like surface ch
and angiogenic lymphocytes and have little capacity to form perfusing vessels or i
avidly secrete angiogenic growth factors. EC-CFUs are depressed in association wi
EC-CFUs therefore serve as a marker of cardiovascular health and possibly indicat
injury. The nomenclature for this population requires revision. (B) The endothelial
cells grown on type I collagen and appear after 2 to 3 weeks of cell culture. ECFC
from nonhematopoietic (CD45) cells expressing CD34. ECFCs have robust prolife
thelial progenitor cell.ascular repair mechanisms. eIt is interesting to note that despite an incomplete
nderstanding of the fundamental basic science govern-
ng EPC biology, numerous clinical studies utilizing
PC populations as cell therapy have been conducted in
he setting of acute myocardial infarction, chronic left
entricular dysfunction, and peripheral vascular disease
59). Although frequently yielding encouraging results,
utologous cell therapy has disappointingly, but perhaps
nsurprisingly, failed to provide marked or sustained
linical benefit. A greater understanding of EPC biology
s urgently required if we are to harness their therapeutic
otential in the treatment of patients with cardiovascular
isease.
PCs and Iatrogenic Vascular Injury
he role of EPCs after the vascular injury resulting from
alloon angioplasty and stenting has not been widely stud-
ed. Experimental models of arterial injury confirm that
one marrow-derived mononuclear cells home to areas of
rom a nonadherent population of mononuclear cells cultured on fibronectin and
ristics; however, it is now recognized that EC-CFUs are composed of monocytes
rate directly into vascular structures. EC-CFUs exhibit phagocytic activity and
iovascular disorders and are mobilized in response to cardiovascular stress.
dividual’s capacity to exert a hematopoietic and angiogenic response to tissue
-forming cell (ECFC) assay. ECFCs are generated from adherent mononuclear
orphologically indistinguishable from mature endothelial cells and are derived
potential and the capacity to form perfusing blood vessels in vitro. EPC  endo-rated f
aracte
ncorpo
th card
e an in
colony
s are m
rativendothelial denudation, accelerate re-endothelialization, re-
s
p
c
p
e
o
f
p
(
t
3
c
t
c
p
a
i
i
d
m
g
h
c
g
P
B
d
1557JACC Vol. 55, No. 15, 2010 Padfield et al.
April 13, 2010:1553–65 Endothelial Progenitor Cells and PCItore endothelial function, and attenuate neointimal hyper-
lasia (Table 2) (60–65). To date, there have been few
linical studies that have specifically addressed the role of
utative EPC populations after angioplasty (Table 3).
Studies of EPCs in patients undergoing PCI have largely
xamined the behavior of EC-CFUs. Unfortunately, many
f the studies were small and did not include a control group
or comparison. Initially, EC-CFUs were measured in
atients undergoing peripheral angioplasty by Bonello et al.
48), who reported an increase in circulating mature endo-
helial cells immediately after angioplasty, with a 2- to
-fold increase in EC-CFUs at 24 h. These findings were
onfirmed by Marboeuf et al. (49), who added that mobiliza-
reclinical Studies of Putative Endothelial Progenitor Cells After VaTable 2 Preclinical Studies of Putative Endothelial Progenitor C
First Author,
Year (Ref. #) Model Number of Subject
Walter et al.,
2002 (65)
Murine Tie-2/lacZ BM transplant
recipients subjected to balloon-
mediated arterial injury and
pretreatment with simvastatin or
placebo
18 placebo,
34 simvastatin
Werner et al.,
2002 (63)
Murine GFP BM transfection followed
by wire-mediated arterial injury and
pretreatment with rosuvastatin or
placebo
5 placebo, 4 rosuvasta
Werner et al.,
2003 (62)
Intravenous cell therapy after wire-
mediated murine arterial injury
6 vascular injury
Fujiyama et al.,
2003 (40)
Intravenous cell therapy versus saline
after balloon-mediated murine
arterial injury
12 vascular injury,
12 controls
Kong et al.,
2004 (61)
G-CSF versus control before balloon-
mediated murine arterial injury
5 G-CSF, 5 controls
Nowak et al.,
2004 (41)
Intravenous cell therapy after balloon
injury in mice using CD14/CD11b
cells expressing, Tie-2, Tie-2,
KDR, KDR, or saline control
6 cell therapy, 6 contr
Elsheikh et al.,
2005 (39)
Intravenous cell therapy using GFP-
transduced cells after balloon-
mediated arterial injury in mice
10 CD14KDR cells,
10 CD14KDR ce
6 controls
Yoshioka et al.,
2006 (60)
G-CSF after wire-mediated arterial
injury in mice; treatment pre- and
post-arterial injury versus post-
arterial injury alone
22 G-CSF, 20 controls
Takamiya et al.,
2006 (64)
1. G-CSF before balloon-mediated
arterial injury in rats
2. GFP BM-transfected mice subjected
to balloon-mediated arterial injury
10 G-CSF, 5 placeboM  bone marrow; Di-Ac-LDL  diacetylated low-density lipoprotein; EPC  endothelial progenitor cell;
omain receptor; MCP  monocyte chemoattractant protein; MNC  mononuclear cell.ion of EC-CFUs correlated with plasma C-reactive protein
oncentrations. EC-CFUs are also mobilized after PCI in
atients with acute coronary syndromes (51). However, in the
bsence of a control group of patients managed conservatively,
t is difficult to determine whether EC-CFUs were mobilized
n response to myocardial infarction or discrete vascular injury
uring PCI.
In our own studies, the number of EC-CFUs were
easured in 54 patients undergoing elective coronary an-
iography (8). EC-CFUs were increased in patients who
ad follow-up intervention, but, importantly, were un-
hanged in those patients who underwent diagnostic an-
iography alone (8). The finding of an increase in EC-
ar InjuryAfter Vascular Injury
Putative EPCs Effect
Di-Ac-LDLlectin MNCs Simvastatin enhanced EPC mobilization after
vascular injury and increased their
adhesive capacity; re-endothelialization
was accelerated by BM-derived cells and
neointimal hyperplasia was reduced
Sca 1KDR cells of BM origin Rosuvastatin enhanced BM-derived EPC
mobilization after vascular injury; re-
endothelialization was accelerated by
BM-derived cells and neointimal
hyperplasia was reduced
Spleen-derived Di-Ac-LDLlectin
MNCs with (EPC) or without
(MNC) a period of culture in
endothelial growth medium
Cell therapy enhanced re-endothelialization in
splenectomized animals and was associated
with a reduction of neointima formation, but
MNCs were more effective than EPCs
BM: CD14CD34 CD14-CD34;
PB CD14CD34
Compared with saline placebo, BM-derived
CD34 cells and both PB- and BM-derived
CD14 cells up-regulated endothelial
markers, accelerated neoendothelialization.
and inhibited neointimal hyperplasia after
activation with MCP-1
CD34KDR G-CSF enhanced EPC mobilization after
vascular injury; re-endothelialization was
accelerated by BM-derived cells and
neointimal hyperplasia was reduced
Myeloid cells (CD14, CD11b)
expressing KDR or Tie-2
CD14KDR and CD14Tie-2 displayed
endothelial characteristics in culture and
enhanced re-endothelialization of denuded
arteries with an associated reduction in
neointimal hyperplasia
CD14KDR CD14KDR Unlike CD14KDR cells, CD14KDR cells
exhibited an endothelial phenotype in
culture and contributed to
neoendothelialization
CD34KDR G-CSF reduced neointimal hyperplasia in
association with mobilization of bone
marrow-derived EPCs and accelerated re-
endothelialization compared with control;
the effect was enhanced if administered
before injury; few BM-derived cells
contributed to neoendothelium
CD117KDR 1. G-CSF enhanced EPC mobilization after
vascular injury; re-endothelialization was
accelerated and neointimal hyperplasia
was reduced
2. GFP expressing BM-derived cells contribute
to neoendothelializationsculells
s
tin
ols
lls,G-CSF  granulocyte colony–stimulating factor; GFP  green fluorescent protein; KDR  kinase
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Endothelial Progenitor Cells and PCI April 13, 2010:1553–65FUs within the first 24 h of angioplasty is consistent and
uggests a role for these cells in the immediate response to
ascular injury (8,48–51). Few studies have addressed
hether EC-CFU mobilization influences the development
f ISR and the need for target vessel revascularization. In a
etrospective study, George et al. (66) demonstrated that in
atients presenting with proliferative as opposed to focal
SR, EC-CFUs were reduced both in number and adhesive
apacity, suggesting that a deficiency in circulating progenitors
ight predispose to aggressive neointimal hyperplasia. This
tudy did not detect a difference in the number of EC-CFUs
etween patients with and without angiographic restenosis.
owever, 2 other groups later reported a decrease in EC-
FUs in patients presenting with restenosis, and these de-
reased EC-CFUs had reduced proliferative and migratory
linical Studies of Putative EPCs After Percutaneous Coronary inteTable 3 Clinical Studies of Putative EPCs After Percutaneous C
First Author,
Year (Ref. #) Study Design Number of Subjects
George et al.,
2003 (66)
Retrospective; restenosis versus
no restenosis
16 restenosis,
11 no restenosis
Schober et al.,
2005 (73)
Prospective; elective PCI with
no control group
17 PCI
Bonello et al.,
2006 (48)
Prospective; elective PCI with
no control group
15 PCI
Matsuo et al.,
2006 (68)
Retrospective; restenosis versus
no restenosis
16 restenosis,
30 no restenosis
Banerjee et al.,
2006 (50)
Prospective; PCI in elective and
ACS patients with diagnostic
angiography control group
20 elective PCI,
10 ACS PCI,
8 controls
Lei et al.,
2007 (67)
Retrospective; angiographic
restenosis vs. no restenosis
15 restenosis,
17 no restenosis
Inoue et al.,
2007 (74)
Prospective; elective PCI with
no control group
40 PCI
Marboeuf et al.,
2008 (49)
Prospective; peripheral arterial
intervention with no control
group
14 angioplasty
Garg et al.,
2008 (51)
PCI in NSTEMI with no control group 20 PCI
Thomas et al.,
2008 (70)
Prospective; elective PCI with
no control group
20 PCI
Egan et al.,
2009 (72)
Prospective; elective PCI versus
diagnostic angiography
10 PCI, 13 controls
Lee et al.,
2009 (69)
Prospective; elective PCI in
diabetics; no control group
8 patients
Mills et al.,
2009 (8)
Prospective; elective PCI versus
diagnostic angiography
27 PCI; 27 controls
CS acute coronary syndrome; BMS bare-metal stent(s); CEC circulating endothelial cell; DE
s in Table 2.apacity as well as increased senescence (67,68). mIn addition to EC-CFUs, mobilization of ECFCs and
D45CD34 has been detected within hours of acute
yocardial infarction in small preclinical and clinical stud-
es. One might speculate that PCI will exert a similar effect,
lthough no studies have specifically examined ECFC or
D45CD34 cells after PCI. The clinical outcome of
atients with comparatively high or low ECFCs undergoing
CI is also unknown. Two small clinical studies demon-
trated a decrease in CD34KDR (CD45/) EPCs
ithin the first few hours after coronary angioplasty, al-
hough neither had control groups and interpretation is
hallenging (69,70). Although homing of circulating pro-
enitors to sites of denuded endothelium is a possible
xplanation, it is more likely that this decrease is due to the
ormal diurnal variation of EPCs (71). Egan et al. (72)
ionary intervention
utative EPCs Studies Effect of Angioplasty
s No difference in EC-CFUs in those presenting with or
without angiographic restenosis, but fewer
EC-CFUs in those presenting with diffuse vs. focal
restenosis and reduced adhesive capacity in
restenosis
Mobilization of CD34 after PCI predicts restenosis
and correlates with late lumen loss
D45CD34, EC-CFUs CECs were increased 6-fold at 6 h, CD45CD34
cells increased 2.6-fold at 6 h, and EC-CFU
increased 2.6-fold at 24 h
s EC-CFUs 2-fold greater in patients without ISR and
increased senescence in EC-CFUs of patients
with ISR
s, CD34CD31 No change in CD34CD31 with PCI in ACS or
diagnostic angiography but 1.4-fold increase in
EC-CFUs with elective PCI
s, CD34KDR EC-CFUs 3.5-fold greater in patients without ISR;
reduced proliferative and migratory capacity in
EC-CFUs of patients without ISR but no difference
in adhesive capacity
CD34 increased 3-fold after BMS at 7 days, but
decreased by 30% after DES at 7 days
s EC-CFUs increased 2.5-fold at 24 h
s EC-CFUs increased 1.3-fold at 24 h
, CD34CD45, CD133,
4CD133, CD34KDR,
33KDR
Transient decrease in all populations at 6 h post-PCI
, KDR, CD133, CD117,
4KDR, CD34CD117,
4CD31, CXCR4
Compared with angiography, CD133, CD117,
CD34CD117, CD34CD31, and CXCR4cells
increased 6–12 h after PCI; no difference in
CD34, KDR, or CD34KDR cells; CXCR4
expression correlated with freedom from angina
at 1 yr
KDR Transient decrease of 50% in first 4 h after PCI
s, CD34KDR EC-CFUs increased 3-fold 24 h after PCI, but
CD34KDR cells were unchanged and neither
were affected by diagnostic angiography alone
g-eluting stent(s); NSTEMI non–ST-segment elevation myocardial infarction; other abbreviationsrventoron
P
EC-CFU
CD34
CEC, C
EC-CFU
EC-CFU
EC-CFU
CD34
EC-CFU
EC-CFU
CD34
CD3
CD1
CD34
CD3
CD3
CD34
EC-CFUeasured a variety of surface markers expressed on mono-
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April 13, 2010:1553–65 Endothelial Progenitor Cells and PCIuclear cells including CD34, CD133, KDR, CD117,
D31, and CXCR4 in patients undergoing PCI, diagnos-
ic coronary angiography alone, and healthy controls. In
his small study, patients with coronary artery disease had
ower resting levels of CD34, CD133, CD117,
D34CD117, CD34CD31, and CXCR4 cells
ompared with healthy controls. After PCI, they observed
n increase in those cells expressing CD133, CD117,
D34/CD31, CD34/CD117, and CXCR4 within 6 to
2 h (72). CXCR4 is thought to be integral to EPC homing
nd integration, and it is of interest to note that reduced levels
f CXCR4 correlated with the incidence of angina at 1 year.
lthough underpowered to address clinical outcomes, this
tudy suggests a role for CXCR4 in EPC homing and
ntegration at the site of vascular injury after PCI.
CD34CD45 mobilization within the first 6 h after
CI has been reported, and, interestingly, the magnitude of
D34CD45 mobilization independently predicts subse-
uent ISR (73,74). It is challenging to interpret these
ndings in light of our understanding of the behavior of
D45CD34 cells in vitro. It is possible that an exagger-
ted response by hematopoietic precursors (CD45) over
ndothelial precursors (CD45) after PCI may favor a
aladaptive response to vascular injury, therefore leading to
estenosis. Further prospective studies are needed to deter-
ine the clinical relevance of these putative EPC popula-
ions in PCI-associated vascular injury.
ypothetical role of EPCs in vascular injury. We suggest
hat circulating EPCs play a critical role in the response to
atrogenic vascular injury from PCI (Fig. 2). We hypothesize
hat EC-CFUs precursors, composed of angiogenic monocytes
nd lymphocytes, are mobilized early after vascular injury,
ome to sites of vascular injury, and avidly secrete angiogenic
actors encouraging resident endothelial cell proliferation and
igration. Over a period of weeks and months, bone marrow-
erived progenitors proliferate and contribute to effective re-
ndothelialization and the restoration vascular homeostasis. A
obust response by the bone marrow may lead to early homing
f EC-CFU precursors to sites of vascular injury with subse-
uent recruitment and integration of EPCs to the endothelial
onolayer, facilitating rapid recovery of normal endothelial
unction and vascular homeostasis. Alternatively, an inade-
uate EC-CFU/EPC response after PCI may result in delayed
e-endothelialization and persistent inflammation, thereby po-
entiating smooth muscle hypertrophy and extracellular matrix
eposition, leading to restenosis and symptoms of myocardial
schemia.
Prospective studies examining the relevance of EC-CFUs
nd ECFCs in angioplasty-related vascular injury and its
omplications, such as restenosis and stent thrombosis, are
waited.
herapeutic Potential of EPCs in Vascular Injury
urrent strategies to decrease the incidence of complica-
ions after PCI are based on suppressing cellular prolifera- iion rather than enhancing vascular repair. Drug-eluting
tents have dramatically reduced the incidence of early ISR,
ut local antiproliferative therapy may interfere with vascu-
ar healing and prevent formation of a functional endothelial
ayer (75). Therapies designed to mobilize endothelial
rogenitors or to increase their ability to home to the site of
tent implantation and facilitate vascular repair are attractive
nd have the potential to improve clinical outcomes after
CI. These approaches fall into 3 broad categories: phar-
acological, cellular, and stent-based therapies.
harmacological therapy. The mechanisms responsible
or the mobilization of EPCs have been reviewed exten-
ively elsewhere (76,77). EPC mobilization is thought to
ccur through activation of the phosphatidylinositol 3-ki-
ase/Akt pathway by angiogenic factors that stimulate
ndothelial nitric oxide synthase (eNOS). Increased nitric
xide bioavailability leads to cleavage of intercellular adhe-
ions between stem cells and stromal cells of the bone
arrow by proteinases, such as elastase, cathepsin G, and
atrix metalloproteinases, and mobilization of EPCs into
he circulation (78). Reduced nitric oxide bioavailability is
vident in patients with cardiovascular risk factors and is
ntegral to the development of atherosclerosis (79). Disor-
ered function of eNOS, such as that occurring in patients
ith diabetes mellitus, is thought to be in part responsible
or impaired mobilization of EPCs in such conditions (80).
one marrow cells treated with an eNOS transcription
nhancer to increase eNOS activity exhibit enhanced mi-
ratory and neovascularization capacity, and, when admin-
stered in a model of hind-limb ischemia, can improve organ
unction. Furthermore, this beneficial effect is reversed by
he use of an eNOS inhibitor, strongly implicating nitric
xide in the process of vascular repair and neovasculariza-
ion (81). Detailed mechanistic data regarding EPC mobili-
ation in the context of discrete vascular injury, however, are
imited. There are numerous factors thought to induce EPC
obilization including VEGF, fibroblastic growth factor,
rowth hormone, insulin-like growth factor, angiopoietin,
tromal cell-derived factor-1, erythropoietin, eostrogens,
-CSF, statins, angiotensin receptor blockers, and peroxisome
roliferator-activated receptor antagonists. Several of these
ave been examined in the context of discrete vascular injury as
otential therapeutic strategies for the mobilization of EPCs.
TATINS. Statins mobilize CD34 and KDR cells into
he peripheral circulation (82) in a dose-dependent manner
83). Statins also increase the formation of EC-CFU (84)
nd ECFC (85) colonies and can induce in vitro differen-
iation of CD14 and CD34 cells toward an endothelial
henotype (86). This has prompted investigators to examine
he effect of statins on EPCs in the context of acute vascular
njury. Walter et al. (65) demonstrated an accelerated rate of
e-endothelialization and a reduction in neointimal hyper-
lasia in rats treated with simvastatin after balloon-
ediated arterial injury; an effect associated with an increasen quantity and adhesive capacity of Ac-LDLBS-1-lectin
c
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Endothelial Progenitor Cells and PCI April 13, 2010:1553–65ells in culture. Although this in vitro definition of an EPC
s relatively nonspecific, these studies did use a Tie-2/LacZ
one marrow transplant model to demonstrate that the
Figure 2 Hypothetical Role of Circulating Progenitor Cells Afte
The endothelial monolayer acts as a nonadhesive surface for platelets and leukoc
ing concentrations of the precursors of endothelial cell colony-forming units (EC-CF
with atherosclerotic disease. (B) Intracoronary stent placement forcefully pushes t
underlying artery, exposing collagen and tissue factor, activating platelets and the
absence of an intact endothelium, local platelet/platelet and platelet/leukocyte co
temic inflammation. We hypothesize a biphasic response to vascular injury caused
tion of the precursors of EC-CFUs involving angiogenic monocytes and lymphocytes
encouraging resident endothelial cell proliferation and migration and the mobilizati
vascular injury. (D) Over a period of weeks and months, progenitor cells proliferate
sis. (E) An inadequate EC-CFU/EPC response after percutaneous coronary interven
tiating smooth muscle hypertrophy and extracellular matrix deposition, leading to r
the bone marrow leads to rapid homing of EC-CFU precursors to sites of vascular
rapid re-endothelialization and recovery of normal endothelial function and vascula
tor; GM-CSF  granulocyte-macrophage- colony stimulating factor; HGF  hepatocy
cular endothelial growth factor; VEGFR2  vascular endothelial growth factor recepeoendothelium in statin-treated animals was derived from sone marrow, supporting the presence of an EPC. Werner
t al. (63) performed similar studies with rosuvastatin and
btained confirmatory findings. Fuduka et al. (87) demon-
ogenic Injury
nd regulates fibrinolysis and vascular tone. (A) Under resting conditions, circulat-
d circulating endothelial progenitor cells (EPCs) are low, particularly in patients
tructive plaque out of the way, but causes damage to the endothelium and
lation cascade, which may result in acute or subacute stent thrombosis. In the
es form, and intense local inflammatory infiltrate ensues with detectable sys-
rcutaneous coronary intervention. (C) The early response consists of mobiliza-
FU precursors home to the site of injury and avidly secrete angiogenic factors,
homing of bone marrow-derived and local endothelial progenitors to the site of
ributing to effective re-endothelialization and the restoration vascular homeosta-
ay lead to delayed re-endothelialization and persistent inflammation, thus poten-
sis and symptoms of myocardial ischemia. (F) However, a robust response by
ith recruitment and integration of EPCs to the endothelial monolayer, facilitating
ostasis. CFU  colony-forming unit; G-CSF  granulocyte-colony stimulating fac-
growth factor; IL  interleukin; MMP  matrix metalloproteinase; VEGF  vas-r Iatr
ytes a
Us) an
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April 13, 2010:1553–65 Endothelial Progenitor Cells and PCIaired re-endothelialization caused by sirolimus-coated
tents; however, in contrast to the afore mentioned studies,
his effect did not seem to be mediated through mobilization
f bone marrow-derived progenitors but rather through
nhancing proliferation of mature endothelial cells adjacent
o the stented segment. On the basis of this small study, the
nvestigators speculated that the beneficial effects of statins
n EPCs were insufficient to counter the inhibitory effects
f sirolimus. Enhanced mobilization and function of EPCs
ay in part explain the reduced rate of ISR after PCI that
s observed in patients treated with statins (88).
-CSF. G-CSF has no established role in the treatment of
ardiovascular disease, but is used routinely for the mobili-
ation of EPCs for autologous bone marrow transplant
ecipients. G-CSF induces release of elastase and cathepsin
from neutrophils that cause release of progenitors from
he stem cell niche into the bloodstream. G-CSF also
obilizes a variety of putative EPC phenotypes including
C-CFUs (89,90), CD34CD133 and CD133KDR
90) c-KitKDR(64), CD34KDR (60), and
D34CD133KDR (89), and several studies demon-
trated a beneficial effect of G-CSF on re-endothelialization
60,61,64,91). Kong et al. (61) and Takamiya et al. (64)
sed G-CSF to accelerate re-endothelialization and suc-
essfully attenuate neointimal hyperplasia in balloon-injured
nimals. Yoshioka et al. (60) also demonstrated that G-CSF
obilized CD34KDR cells and accelerated re-
ndothelialization, but, in contrast to the study by Takamiya
t al., very few bone marrow-derived EPCs contributed to
e-endothelialization. The mechanism by which G-CSF
educes neointimal hyperplasia is therefore unclear. Yo-
hioka et al. speculated that G-CSF may increase prolifer-
tion and migration of adjacent endothelial cells either
irectly or through stimulation by attaching EPCs. It is
ossible that even a marginal increase in attaching EPCs
ight be enough to increase the secretion of angiogenic
actors (92–94).
Shi et al. (91) used G-CSF to accelerate endothelializa-
ion of Dacron grafts implanted in the aortas of dogs, but
espite enhanced endothelialization, animals treated with
-CSF had considerably more neointimal formation than
ontrols. Concordant with this preclinical study, intracoro-
ary G-CSF administered to patients with myocardial
nfarction was associated with an increased incidence of
SR, despite improvements in left ventricular ejection frac-
ion (95). This effect may have been mediated through the
onspecific proinflammatory actions of G-CSF and the
obilization of smooth muscle progenitors from the bone
arrow. The nonspecific nature of the effects of G-CSFs
ampers its translation into a targeted therapy for vascular
epair.
EROXISOME PROLIFERATOR-ACTIVATED RECEPTOR AGONISTS.
eroxisome proliferator-activated receptor agonists inhibit vas-
ular smooth muscle proliferation and migration, improve
ndothelial function, and accelerate re-endothelialization. This tan lead to an attenuation of neointimal formation in mice
ubjected to femoral angioplasty.Wang et al. (96) attributed this
ffect to the ability of roziglitazone to drive pleuripotent
one marrow-derived vascular progenitors toward an endo-
helial phenotype and away from a smooth muscle pheno-
ype. Peroxisome proliferator-activated receptor agonists
ay therefore have a role to play in augmenting a maladap-
ive response to iatrogenic vascular injury, although con-
erns remain regarding the safety profile of these drugs in
atients with ischemic heart disease (97).
RYTHROPOIETIN. The effects of erythropoietin on the re-
ponse to discrete vascular injury are similarly favorable in
erms of re-endothelialization, possibly through eNOS-
ependent mobilization of Sca-1KDR cells, enhanced pro-
iferation of resident endothelial cells, and reduced apoptosis of
he injured artery (98). Erythropoietin has also been associ-
ted with an increased incidence of neointimal proliferation
espite adequate re-endothelialization in animal studies,
gain possibly as a result of the nonspecific mobilization of
mooth muscle progenitors (99). Ongoing clinical trials of
rythropoietin in patients with acute myocardial infarction,
he REVEAL (Reduction of Infarct Expansion and Ven-
ricular Remodeling With Erythropoietin After Large
yocardial Infarction) (100) and HEBE-III (A prospec-
ive, randomized, double blind, placebo controlled clinical
tudy to examine the effects of a single bolus erythropoietin
n left ventricular function in patients with an acute
yocardial infarction) (101) trials, will address whether
rythropoietin will have a favorable effect on vascular
emodeling.
STROGEN. Estrogens enhance vascular repair in models of
rterial injury through eNOS-dependent mobilization and
roliferation of bone marrow-derived EPCs (102) and
educed apoptotic signaling through the actions of
aspase-8 (103).
ellular therapy. Intravenous and intracoronary infusions
f bone marrow-derived cells have been used in an attempt
o accelerate vascular healing. Using animal models of
ndovascular injury, transfusion of mononuclear cells cul-
ured in angiogenic medium to produce EPCs has success-
ully accelerated re-endothelialization and attenuated neo-
ntimal hyperplasia in several studies (62,93,104,105).
lthough effective, it is difficult to be certain whether the
ells infused in these studies truly differentiated to become
ndothelial cells. It remains possible that the beneficial
ffects on the development of neointimal hyperplasia ob-
erved were mediated through a paracrine influence of
ngiogenic monocyte and lymphocyte populations con-
ained in mononuclear preparations. The populations used
ere selected using fairly nonspecific characteristics, and it
s certain that the cell preparations infused were heteroge-
eous in their composition. There have been no clinical
tudies using infused progenitor cells specifically to influ-
nce restenosis. Data regarding the transfusion of progeni-
or cells in human studies are derived from studies examin-
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Endothelial Progenitor Cells and PCI April 13, 2010:1553–65ng the effect of mononuclear cell infusion on left ventricular
ysfunction and myocardial ischemia (106). The results of
hese studies have been largely disappointing in terms of
roviding a sustained clinical benefit, although they do
uggest that intracoronary transfusion of mononuclear cells
s feasible and safe (107). Concerns that infusion of mono-
uclear cells may increase inflammatory signaling and
mooth muscle proliferation are well founded theoretically,
nd there are some reports of an increased incidence of
oronary events including restenosis and thrombosis after
nfusion of CD133 progenitor cells (108).
tent-based therapy. Technological advances and the evo-
ution of intracoronary stents provide a potential vehicle to
eliver novel therapies directly to the site of vascular injury.
ttempts to coat intracoronary stents with endothelial
itogens, such as VEGF, have not been encouraging in
erms of re-endothelialization (109). However gene-eluting
tents directly delivering naked plasmid DNA encoding for
EGF-2 can accelerate re-endothelialization and reduce
umen loss in animal models (110).
The Genous Bio-engineered R stent (OrbusNeich, Hong
ong) is coated with monoclonal antibodies directed
gainst CD34 and is designed to attract EPCs and therefore
ncourage re-endothelialization. Genous stents have already
rogressed to phase II and III clinical trials and have been
eployed in 5,000 patients. Preliminary data from small
egistries reported major adverse cardiovascular event rates
anging from 7.9% to 13% (111–114). However, data from
he e-HEALING registry on 4,996 patients suggest a
avorable target lesion revascularization rate of 4.4% and a
ajor adverse cardiovascular event rate of 7.7%, with a low
ncidence of subacute (0.5%) and late (0.3%) stent throm-
osis (115). Interestingly, the HEALING II registry re-
orted that patients with normal CD34KDR EPC titers
ad lower rates of ISR compared with those patients with
educed circulating EPCs (late luminal loss 0.53 0.06 mm
s. 1.01  0.07 mm). Furthermore, a subgroup of 30
atients in this nonrandomized study underwent serial
valuation using intravascular ultrasound, and regression of
eointimal volume was observed in patients with higher
oncentrations of EPCs (112).
The first randomized, controlled trial in a small cohort of
atients with ST-segment elevation myocardial infarction
as recently presented and demonstrated a trend toward
ncreased restenosis with the Genous stent when compared
ith a standard chromium-cobalt stent (116). Restenosis
ith CD34 capture stents may occur as a consequence of
onspecific binding with non-EPCs. CD34 is common to a
umber of progenitors including smooth muscle progenitor
ells (117). Circulating smooth muscle progenitor cells are
oorly characterized, but are known to contribute to neo-
ntimal hyperplasia (118) with both CD34 and CD133
etected at increased levels in the neointima of restenotic
esions compared with de novo lesions (119). The effect of
ndiscriminate binding of CD34 cells to intracoronary
tents could theoretically result in an exaggerated restenoticffect due to proliferation of smooth muscle progenitors,
articularly as individuals susceptible to ISR, such as pa-
ients with diabetes mellitus. TRIAS (Tri-stent Adjudica-
ion Study) is ongoing and will directly compare the safety
nd efficacy of the Genous stent with bare metal and
rug-eluting stents. As our understanding of EPC biology
mproves, so too will our ability to use intracoronary stents
o modulate the cellular response to vascular injury and
irectly enhance re-endothelialization after iatrogenic vas-
ular injury through gene and drug delivery or progenitor
ell capture.
onclusions
ndothelial regeneration is a key component of an effective
esponse to the vascular injury associated with PCI. Under-
tanding the mechanisms involved in this process will provide
he rationale for therapies that target the acceleration of
ascular healing. Much progress has been made toward deter-
ining the variety of populations involved in the cellular
esponse to vascular injury. Although it is clear that circu-
ating progenitors contribute to vascular healing, it is also
vident that their function is dependent on both the local
icroenvironment and a synergy between other populations
obilized in response to the vascular insult. For us to use
PCs as an effective treatment modality, further studies are
equired to elucidate not only the target cell type of interest,
ut also the involvement of the microenvironment on
ellular behavior, the best mode of delivery or mobilization
o the site of injury, and the need for adjunctive therapy to
ptimize EPC function.
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